BioNTech's Quarter Turns a Profit, but the Market Is Grading on a Curve

BioNTech returned to the black in the third quarter of 2026, posting a net profit of EUR 184.5 million on revenue of EUR 1.29 billion. That swing reverses a net loss of EUR 28.7 million in the same period a year earlier. The top line, however, tells a less cheerful story: revenue slipped as demand for COVID-19 vaccines continued to fade.

The quarterly result stands in sharp contrast to the cumulative picture. Over the first nine months of 2026, the company ran a net loss of EUR 1.17 billion, according to media reports. Weighing on the books were research and development spending in oncology and the shrinking COVID-19 vaccine business. BioNTech has also flagged the planned closure of its Idar-Oberstein, Marburg and Tübingen sites, a move expected to affect roughly 1,800 employees.

Forecast Floor Raised

Alongside the quarterly figures, BioNTech lifted the lower bound of its 2026 revenue guidance to EUR 1.7 billion from EUR 1.6 billion. The upper end was left unchanged at EUR 1.9 billion, nudging the midpoint of the expected range higher. That guidance covers full-year revenue, while the EUR 184.5 million profit applies to the third quarter alone. The company filed the results and accompanying corporate disclosures with the US Securities and Exchange Commission on Tuesday via Form 6-K.

The stock has drawn support from the broader vaccine complex. Shares rose 2.3% to close at EUR 78.25, with media reports placing BioNTech among the vaccine names that advanced around Moderna's quarterly update. Moderna had reported a profit and raised its full-year outlook.

Analysts Keep the Faith, at a Lower Price

Sell-side conviction has held up even as price targets come down. Wells Fargo's Mohit Bansal cut his target to $125 from $140 on Wednesday while keeping an "Overweight" rating. Morgan Stanley's Terence Flynn followed the same pattern, trimming his target to $106 from $114 and sticking with "Overweight."

The shared direction is telling: lower marks paired with positive calls amount to graded confidence rather than a change of heart. Whether that confidence holds depends on how the business develops and what the clinical data ultimately show. The stock added 2.3% on Friday as well, though a single session says little about the longer-term case.

A Milestone With a Measured Payoff

A concrete test arrived on October 26, when BioNTech and DualityBio reported that their Phase 3 DYNASTY-Breast02 study met its primary endpoint. The improvement in progression-free survival was statistically significant, but the magnitude was moderate. That combination validates the trial while limiting how much weight the result can carry — reaching an endpoint is one thing, and the size of the benefit is another.

Overall survival data were not yet mature, so a fuller clinical assessment hinges on how that portion of the results develops. For investors, the read-across is twofold: the vaccine business shapes part of the economic base, while clinical results must demonstrate how durable the outlook beyond it really is. The trimmed price targets fit that more cautious weighting. The study progress supports a more convincing valuation — provided further data back up its clinical value.